Alps Advisors Inc. boosted its position in Ocular Therapeutix Inc. (NASDAQ:OCUL) by 25.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,792 shares of the biopharmaceutical company’s stock after buying an additional 6,976 shares during the period. Alps Advisors Inc.’s holdings in Ocular Therapeutix were worth $172,000 as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Ocular Therapeutix by 1.5% in the first quarter. Geode Capital Management LLC now owns 70,396 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 1,042 shares during the period. State Street Corp increased its stake in Ocular Therapeutix by 13.8% in the first quarter. State Street Corp now owns 205,586 shares of the biopharmaceutical company’s stock worth $1,989,000 after buying an additional 24,939 shares during the period. Acadian Asset Management LLC purchased a new stake in Ocular Therapeutix during the second quarter worth $422,000. Finally, Prescott Group Capital Management L.L.C. purchased a new stake in Ocular Therapeutix during the second quarter worth $1,750,000. 78.45% of the stock is currently owned by institutional investors and hedge funds.
Shares of Ocular Therapeutix Inc. (NASDAQ:OCUL) traded down 5.96% on Friday, reaching $6.79. 2,494,435 shares of the company’s stock were exchanged. The company’s market cap is $168.53 million. Ocular Therapeutix Inc. has a 12 month low of $4.04 and a 12 month high of $17.34. The firm’s 50-day moving average price is $6.78 and its 200 day moving average price is $7.94.
Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.03. Ocular Therapeutix had a negative net margin of 2,519.61% and a negative return on equity of 52.44%. The business had revenue of $0.44 million for the quarter, compared to analyst estimates of $0.55 million. During the same quarter in the previous year, the firm posted ($0.45) earnings per share. The company’s revenue for the quarter was down 3.9% on a year-over-year basis. Equities research analysts predict that Ocular Therapeutix Inc. will post ($1.87) EPS for the current fiscal year.
A number of research firms recently weighed in on OCUL. Zacks Investment Research raised Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a research report on Friday, August 12th. JMP Securities began coverage on Ocular Therapeutix in a research report on Thursday, August 11th. They set an “outperform” rating and a $5.84 target price on the stock. Finally, BTIG Research reissued a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, July 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Ocular Therapeutix has a consensus rating of “Buy” and a consensus target price of $19.07.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix Inc. (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.